Patents Assigned to Biotechnology, Inc.
  • Patent number: 12214093
    Abstract: Disclosed are methods for treating platelet compositions (e.g. platelet concentrates and/or platelet lysates) with electron beam radiation, where the compositions are in a frozen state during irradiation with the e-beam radiation. The methods can be conducted using e-beam radiation at doses effective to reduce the pathogen content of the compositions while retaining highly beneficial bioactivities of the compositions. Also disclosed are compositions preparable by the methods, and methods and compositions involving the use of the e-beam treated materials.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: February 4, 2025
    Assignee: SEXTON BIOTECHNOLOGIES, INC.
    Inventors: Steven Charlebois, Sreedhar Thirumala
  • Patent number: 12217828
    Abstract: A method, apparatus, and computer-readable medium for efficiently optimizing a phenotype with a combination of a generative and a predictive model, training a phenotype prediction model based on experiential genotype vectors, training a genotype generation model based on sample genotype vectors, generating new genotype vectors, applying the phenotype prediction model to the new genotype vectors to generate scores, determining result genotypes based on a ranking of the available genotypes according to the scores, and generating a result based on the result genotypes, the result indicating one or more genetic constructs for testing.
    Type: Grant
    Filed: February 6, 2023
    Date of Patent: February 4, 2025
    Assignee: TESELAGEN BIOTECHNOLOGY INC.
    Inventors: Eduardo Abeliuk, Andrés Igor Pérez Manríquez, Juan Andrés Ramírez Neilson, Diego Francisco Valenzuela Iturra
  • Patent number: 12203104
    Abstract: The invention is directed to methods involved in the production of flavonoids, anthocyanins and other organic compounds. The invention provides cells engineered for the production of flavonoids, anthocyanins and other organic compounds, where the engineered cells include one or more genetic modifications that increase flavonoid production by increasing metabolic flux to flavonoid precursors and/or reducing carbon losses resulting from the production of byproducts.
    Type: Grant
    Filed: April 13, 2022
    Date of Patent: January 21, 2025
    Assignee: DEBUT BIOTECHNOLOGY, INC.
    Inventors: Jingyi Li, Nicholas Brideau, Joshua Britton, Erik Holtzapple
  • Patent number: 12195542
    Abstract: The invention relates to anti-Tie2 antibodies and methods of using the same.
    Type: Grant
    Filed: November 19, 2020
    Date of Patent: January 14, 2025
    Assignee: Unity Biotechnology, Inc.
    Inventors: Jason Damiano, Kristina Oresic Bender, Richard Theolis, Deepika Bhatnagar, Nina Ly
  • Patent number: 12195770
    Abstract: The disclosure describes novel systems, methods, and compositions for the manipulation of nucleic acids in a targeted fashion. The disclosure describes non-naturally occurring, engineered CRISPR systems, components, and methods for targeted modification of nucleic acids such as DNA. Each system includes one or more protein components and one or more nucleic acid components that together target nucleic acids.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: January 14, 2025
    Assignee: Arbor Biotechnologies, Inc.
    Inventors: Elise Keston-Smith, David A. Scott, David R. Cheng, Winston X. Yan, Pratyusha Hunnewell, Jason Carte
  • Publication number: 20250011423
    Abstract: Soluble TREML1 is involved in many inflammatory diseases and plays an important role in immune suppression. Soluble TREML1 can bind the l-domain of CD11b and induce an immune suppressive phenotype. Thus, soluble TREML1 may be a good target for treating inflammatory diseases. The present invention relates to antibodies that can reduce soluble TREML1 binding to CD11b+ immune cells and their uses for reversing TREML14 induced immune suppression. Anti-TREML1 antibodies provide a novel and potential therapy for these disease conditions such as cancer.
    Type: Application
    Filed: November 15, 2022
    Publication date: January 9, 2025
    Applicant: Ascendo Biotechnology, Inc.
    Inventors: Yen-Ta Lu, Chia-Ming Chang, Yi-Chen Chen, I-Fang Tsai
  • Publication number: 20250002473
    Abstract: The present disclosure relates to at least one entity chosen from a compound of Formula (I), tautomers, stereoisomers or a mixture of stereoisomers, hydrates, and deuterated derivatives thereof, and pharmaceutically acceptable salts of any of the foregoing, and their use as epidermal growth factor receptor (EGFR) degraders for the prevention and treatment of diseases and conditions, e.g., cancer. The present disclosure also relates to pharmaceutical compositions containing such entities, and their use in treating or preventing a disease or disorder associated with EGFR.
    Type: Application
    Filed: June 14, 2024
    Publication date: January 2, 2025
    Applicant: Accutar Biotechnology Inc.
    Inventors: Ji LIU, Pin HUANG, Ke LIU, Wei HE, Yimin QIAN, Jie FAN, Robert Luo
  • Patent number: 12180495
    Abstract: Polynucleotides incorporated into nucleic acid constructs have been introduced into plants and were ectopically expressed. The encoded polypeptides of the invention have been shown to confer at least one regulatory activity and confer earlier flowering, longer floral organ retention, increased cold tolerance, greater tolerance to water deprivation, altered carbon-nitrogen balance sensing, increased low nitrogen tolerance, and/or increased tolerance to hyperosmotic stress as compared to a control plant.
    Type: Grant
    Filed: September 6, 2023
    Date of Patent: December 31, 2024
    Assignees: Mendel Biotechnology, Inc., Monsanto Technology LLC
    Inventors: Jose Luis Riechmann, Oliver J. Ratcliffe, T. Lynne Reuber, Katherine Krolikowski, Jacqueline E. Heard, Omaira Pineda, Cai-Zhong Jiang, Robert A. Creelman, Roderick W. Kumimoto, Paul S. Chomet
  • Patent number: 12180491
    Abstract: An isolated expression enhancer active in a plant, portion of a plant or plant cell, the expression enhancer is provided. The isolated expression enhancer may be selected from the group consisting of nbMT78 (SEQ ID NO:1); nbATL75 (SEQ ID NO:2); nbDJ46 (SEQ ID NO:3); nbCHP79 (SEQ ID NO:4); nbEN42 (SEQ ID NO:5); atHSP69 (SEQ ID NO:6); atGRP62 (SEQ ID NO:7); atPK65 (SEQ ID NO:8); atRP46 (SEQ ID NO:9); nb30S72 (SEQ ID NO:10); nbGT61 (SEQ ID NO:11); nbPV55 (SEQ ID NO:12); nbPPI43 (SEQ ID NO:13); nbPM64 (SEQ ID NO:14); and nbH2A86 (SEQ ID NO:15). Methods for using the isolated expression enhancer are also provided.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: December 31, 2024
    Assignee: ARAMIS BIOTECHNOLOGIES INC.
    Inventors: Pierre-Oliver Lavoie, Marc-Andre D'Aoust, Ko Kato, Shotaro Yamasaki
  • Publication number: 20240425820
    Abstract: Provided are engineered cells containing one or more modifications, such as genetic modifications, for use in allogeneic cell therapy. In some embodiments, the engineered cells are hypoimmunogenic cells. In some embodiments, the engineered cells comprise increased expression of CD46 and CD59.
    Type: Application
    Filed: August 11, 2022
    Publication date: December 26, 2024
    Applicant: Sana Biotechnology, Inc.
    Inventor: Sonja SCHREPFER
  • Publication number: 20240424050
    Abstract: The present disclosure generally relates to compositions comprising dihexa and methods for making or using said compositions. In some aspects, the compositions disclosed herein may comprise one or more additional active ingredients, including lipoic acid, spadin peptide, and/or phenyl-N-tert-butylnitrone. Compositions such as these may be used in certain embodiments, for example, to enhances a subject's hearing or to treat a hearing disorder, etc. In some embodiments, the compositions are topical compositions configured to treat hearing loss via administration, e.g., to the skin behind the outer ear or directly to the eardrum of a subject, etc. In some cases, the compositions disclosed herein may comprise one or more excipients to aid in transdermal delivery. For instance, in certain embodiments, the compositions comprise lecithin and/or other components that may facilitate delivery through the skin.
    Type: Application
    Filed: April 4, 2024
    Publication date: December 26, 2024
    Applicant: Transdermal Biotechnology, Inc.
    Inventor: Nicholas V. Perricone
  • Publication number: 20240425519
    Abstract: Spirocyclic compounds that are KLHDC2 ligands and methods for inhibiting the enzymatic activity of KLHDC2 using the ligands.
    Type: Application
    Filed: October 31, 2022
    Publication date: December 26, 2024
    Applicants: University of Washington, ACCUTAR BIOTECHNOLOGY INC.
    Inventors: Ning ZHENG, Domnita Valeria RUSNAC, Jie FAN, Yimin QIAN, Ke LIU
  • Patent number: 12173077
    Abstract: The present invention is directed to a humanized BCMA antibody or an antigen-binding fragment thereof, comprising VH having the amino acid sequence of SEQ ID NO: 3 and VL having the amino acid sequence of SEQ ID NO: 5. The present invention is also directed to a BCMA chimeric antigen receptor fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) of the present invention, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain. This humanized BCMA-CAR-T cells have specific killing activity against BCMA-positive tumor cells.
    Type: Grant
    Filed: May 31, 2023
    Date of Patent: December 24, 2024
    Assignees: ProMab Biotechnologies, Inc., Forevertek Biotechnology Co., Ltd
    Inventors: Lijun Wu, Vita Golubovskaya
  • Patent number: 12168008
    Abstract: The present invention provides a method of treating a subject afflicted with cancer comprising administering to the subject an effective amount of a PP2A inhibitor.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: December 17, 2024
    Assignees: Lixte Biotechnology, Inc., The United States of America, as Represented by the Secretary Department of Health and Human Services
    Inventors: John S. Kovach, Zhengping Zhuang, Sze Chun Winson Ho, Herui Wang, Rongze Lu
  • Publication number: 20240408171
    Abstract: An aqueous formulation includes a PEDF-derived short peptide (PDSP) having the sequence of one of SEQ ID NO: 1, 2, 3, 5, 6, 8 or 9; boric acid at a concentration of 0.01 mM-923 mM; and a non-ionic tonicity agent. The pH value is around 5.5-8.4. The non-ionic tonicity agent is glycerin, sucrose, mannitol, or sorbitol. A concentration of the PDSP is 0.01%-1% w/v.
    Type: Application
    Filed: January 24, 2022
    Publication date: December 12, 2024
    Applicant: BRIM Biotechnology, Inc.
    Inventors: Frank Wen-Chi Lee, Wayne Wei-Cheng Liaw, Jason Ping-Yen Huang, Emily Hsiao-Han Wang
  • Publication number: 20240408192
    Abstract: Provided herein are lipid particles, such as lenti viral particles, that incorporate or are pseudotyped with a variant Nipah Virus G (NiV-G) envelope glycoprotein, and in some aspects also a fusion (F) protein such as a NiV-F protein or a biologically active portion or variant thereof. Also provided are polynucleotides encoding the variant NiV-G and producer cells for preparation of the lipid particles, such as lentiviral particles, containing the variant NiV-G proteins, as well as methods for preparing and using the lipid particles, such as lentiviral particles.
    Type: Application
    Filed: December 16, 2022
    Publication date: December 12, 2024
    Applicant: Sana Biotechnology, Inc.
    Inventors: Christopher BANDORO, Lauren Pepper MACKENZIE, Jagesh Vijaykumar SHAH, Kyle Marvin TRUDEAU
  • Publication number: 20240409908
    Abstract: The disclosure describes novel systems, methods, and compositions for the manipulation of nucleic acids in a targeted fashion. The disclosure describes non-naturally occurring, engineered CRISPR systems, components, and methods for targeted modification of DNA, RNA, and protein substrates. Each system includes one or more protein components and one or more nucleic acid components that together target DNA, RNA, or protein substrates.
    Type: Application
    Filed: June 13, 2024
    Publication date: December 12, 2024
    Applicant: Arbor Biotechnologies, Inc.
    Inventors: David A. Scott, David R. Cheng, Winston X. Yan
  • Patent number: 12161748
    Abstract: A topical formulation comprising (a) a therapeutically effective amount of tofacitinib; (b) at least one solvent; and (c) optionally one or more other pharmaceutically acceptable excipients is provided. Also provided is a method for treating and/or preventing autoimmune diseases in a subject administering said topical formulation.
    Type: Grant
    Filed: March 26, 2021
    Date of Patent: December 10, 2024
    Assignee: TWI BIOTECHNOLOGY, INC.
    Inventors: Chih-Ming Chen, Guang-Wei Lu, Ling-Ying Liaw, Fan-Lun Liu, Shih-Fen Liao, Chou-Hsiung Chen, Yu-Han Kao, Yu-Yin Chen
  • Publication number: 20240398805
    Abstract: The disclosure provides quinazoline based compounds and pharmaceutical compositions thereof, which are useful for inhibiting EGFR, as well as methods for using such compounds to treat cancer associated with an EGFR or HER2 exon 20 insertion mutation.
    Type: Application
    Filed: February 4, 2022
    Publication date: December 5, 2024
    Applicant: ACCUTAR BIOTECHNOLOGY INC.
    Inventors: Yimin Qian, Wei HE, Robert LUO, Jie Fan
  • Publication number: 20240401064
    Abstract: A bacteria-mediated platform that uses invasive, non-pathogenic bacteria to both produce and intracellularly deliver antibodies, antibody derivatives, and proteins/polypeptides to targeted eukaryotic cells and tissues. The bacteria can contain a prokaryotic expression cassette encoding the protein cargo.
    Type: Application
    Filed: June 2, 2022
    Publication date: December 5, 2024
    Applicant: SiVEC Biotechnologies, Inc.
    Inventors: Lyndsey M Linke, Ashley B Williams, Darcy Mora, Madeline Cox, Timothy Enroth